The stock of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) last traded at $10.44, up 14.35% from the previous session.
AUPH stock price is now 33.12% away from the 50-day moving average and 67.94% away from the 200-day moving average. The market capitalization of the company currently stands at $1.49B.
, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, TANG KEVIN, Director bought 500,000 shares of the company’s stock on Dec 09 ’24. The stock was bought for $4,545,000 at an average price of $9.09. Upon completion of the transaction, the Director now directly owns 8,429,500 shares in the company, valued at $88.0 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 06 ’24, Director TANG KEVIN bought 400,000 shares of the business’s stock. A total of $3,604,000 was incurred on buying the stock at an average price of $9.01. This leaves the insider owning 7,929,500 shares of the company worth $82.78 million. A total of 10.14% of the company’s stock is owned by insiders.
During the past 12 months, Aurinia Pharmaceuticals Inc has had a low of $4.71 and a high of $9.74. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 5.60, and a quick ratio of 5.11. The fifty day moving average price for AUPH is $7.7806 and a two-hundred day moving average price translates $6.1944 for the stock.
The latest earnings results from Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was released for 2024-09-30. The net profit margin was -10.23% and return on equity was -5.78% for AUPH. The company reported revenue of $67.77 million for the quarter, compared to $54.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 24.32 percent.
